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Introduction: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease, which can affect
different organs. Increased proportions of CD4+CD25−Foxp3+ T cells have been described in SLE patients. The exact
role of this cell population in SLE patients still remains unclear. We therefore analyzed this T cell subset in a large
cohort of SLE patients with different organ manifestations.
Methods: Phenotypic analyses, proportions and absolute cell numbers of CD4+CD25−Foxp3+ T cells were
determined by flow cytometry (FACS) in healthy controls (HC) (n = 36) and SLE patients (n = 61) with different
organ manifestations. CD4+CD25−Foxp3+ T cells were correlated with clinical data, the immunosuppressive therapy
and different disease activity indices. In patients with active glomerulonephritis, CD4+CD25−Foxp3+ T cells were
analyzed in urine sediment samples. Time course analyses of CD4+CD25−Foxp3+ T cells were performed in patients
with active disease activity before and after treatment with cyclophosphamide and prednisone.
Results: CD4+CD25−Foxp3+ T cells were significantly increased in active SLE patients and the majority expressed
Helios. Detailed analysis of this patient cohort revealed increased proportions of CD4+CD25−Foxp3+ T cells in SLE
patients with renal involvement. CD4+CD25−Foxp3+ T cells were also detected in urine sediment samples of
patients with active glomerulonephritis and correlated with the extent of proteinuria.
Conclusion: CD4+CD25−Foxp3+ T cells resemble regulatory rather than activated T cells. Comparative analysis of
CD4+CD25−Foxp3+ T cells in SLE patients revealed a significant association of this newly described cell population
with active nephritis. Therefore CD4+CD25−Foxp3+ T cells might serve as an important tool to recognize and
monitor SLE patients with renal involvement.Introduction
Regulatory T cells (Treg) constitute on average 1 to 2% of
human peripheral blood mononuclear cells (PBMC) and
are characterized by their capacity to actively suppress T
cell proliferation in vitro [1]. Treg play an important role
in T cell homeostasis and are critical regulators of immune
tolerance. Quantitative and/or qualitative deficiencies of
Treg have been suggested to contribute to the develop-
ment of autoimmune diseases [2-8].
Treg are best characterized by high expression levels of
the IL-2 receptor α-chain (CD25) [9,10]. In addition the
forkhead family transcription factor (Foxp3) has been de-
scribed as a highly specific intracellular marker molecule* Correspondence: clemens.scheinecker@meduniwien.ac.at
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reproduction in any medium, provided the orfor Treg [11-14]. Helios, a member of the Ikaros transcrip-
tion factor family, has recently been described as a specific
marker for thymic-derived Foxp3+ regulatory T cells
[15,16]. In addition it has been shown that proportions
but not absolute numbers of Foxp3+Helios+ T cell are in-
creased in systemic lupus erythematosus (SLE) patients
and that Foxp3+Helios− T cells are capable of effector
cytokine production [17].
We have recently identified a novel subset of CD4+Foxp3+
Treg that does not express CD25 surface molecules
(CD4+CD25−Foxp3+) [18]. CD4+CD25−Foxp3+ share pheno-
typic characteristics with conventional CD4+CD25+Foxp3+
Treg and convey lower, but still considerable suppression of
T cell proliferation, though not of IFN-γ production, in vitro.
Increased proportions of CD4+CD25−Foxp3+ Treg are ob-
served in particular in SLE patients, a finding that has widely
been confirmed [19-23]. However, the origin, the preciseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Demographic and clinical characteristics of
systemic lupus erythematosus patients
Characteristic Value
Age, years, mean ± SD 40.4 ± 14.5
Gender, female/male, n (%) 56 (91.8%)/5 (8.2%)
Disease duration years, mean ± SD 5.4 ± 4.9
Anti-ds DNA Ab-positive, n (%) 23 (62.3%)
C3, mean ± SD 90.5 ± 26.6
C4, mean ± SD 14.3 ± 7.1
CH50, mean ± SD 110.6 ± 31.9
SLEDAI, mean ± SD 4.2 ± 4.2
ECLAM, mean ± SD 1.9 ± 1.9
SIS, mean ± SD 3.6 ± 2.9
Current prednisone dose, mg/day, mean ± SD 10.4 ± 15.3
Concurrent immunosuppressive therapy, n (%)
Hydroxychloroquine 22 (36.1%)




Organ involvement, n (%)
Skin/active 37 (60.7.1%)/8 (13.1%)
Hematologic/active 23 (37.7%)/10 (16.4%)
Arthritis/active 22 (36.1%)/3 (4.9%)
Serositis/active 8 (13.1%)/2 (3.3%)
Renal/active 25 (40.9%)/13 (21.3%)
SLEDAI, systemic lupus erythematosus disease activity index; ECLAM, European
Consensus Lupus Activity Measurement; SIS, systemic lupus erythematosus
index score.
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of CD4+CD25−Foxp3+ Treg are still enigmatic.
In this study we therefore evaluated if the presence of
CD4+CD25−Foxp3+ cells is associated with a particular
phenotype of organ manifestations in SLE patients. Our
data reveal that CD4+CD25−Foxp3+ that share phenotypic
characteristics with regulatory T cells are increased in pa-
tients with lupus nephritis.
Materials and methods
Patients and controls
SLE patients (n = 61; mean age 45 ± 16.8 years) who ful-
filled at least four of the revised SLE criteria of the Ameri-
can College of Rheumatology [24] were randomly selected
from our outpatient clinic. Healthy volunteers served as a
healthy control (HC) population (n = 36; mean age 42 ±
15.7 years). The disease activity of SLE patients was
assessed using the SLE disease activity index (SLEDAI)
[25], the European Consensus Lupus Activity Measure-
ment (ECLAM) score [26] and the SLE index score (SIS)
[27]. A detailed patient characteristic is shown in Table 1.
Patients were divided into two groups according to their
disease activity as determined by the SLEDAI score. A
SLEDAI score ≥6 was defined as high disease activity and
a SLEDAI score of <6 as low disease activity. Depending
on their clinical status we divided the patients into groups
with active and no active organ involvement at the time of
the patient’s blood draw. Active organ involvement was
defined by clinical and laboratory parameters. The follow-
ing items were considered to be indicative for active organ
involvement: active skin involvement defined as lupus
rash, discoid lupus or photosensitivity; active joint involve-
ment defined as arthritis with synovial swelling; active
hematologic involvement defined as thrombocytopenia,
lymphocytopenia, or leukocytopenia or (Coombs test posi-
tive) hemolytic anemia; active renal involvement defined
as nephritis with proteinuria >0.5 g protein/24 h and/or
active nephritic sediment. In all patients with renal in-
volvement a renal biopsy had been performed and glomer-
ulonephritis was classified according to the World Health
Organization (WHO) classification [28]. All patients with
renal manifestation were classified as having glomerulo-
nephritis WHO III or IV.
Ethical approval for this study was granted by the local
ethics committee of the Medical University of Vienna and
internal review board of the Medical University of Vienna,
Austria. Patients gave written informed consent to partici-
pate in the study and agreed that the findings of the study
will be published in a scientific journal.
Antibodies
The following mAb/conjugates were used in this study: R-
phycoerythrin (PE), phycoerythrin-cyanin5 (PE-Cy5) and
allophycocyanin (APC), PE-Cy7-conjugated mAb againstCD4 (SK3) and CD25 (2A3) were purchased from Becton
Dickinson (San Jose, CA, USA); mAb against Foxp3 (236A/
E7) was obtained from eBiosciences (San Diego, CA, USA);
mAb against CD14 (RMO52) was obtained from Beckman
Coulter (Fullerton, CA, USA), mAb against Helios (22 F6)
was obtained from Biolegend (San Diego, CA, USA).
Phenotypic analyses
PBMC were isolated from heparinized blood by layering
over LSM 1077 Lymphocyte Separation Medium (PAA
laboratories, Pasching, Austria) and density gradient cen-
trifugation at 400 × g. PBMC were resuspended in PBS/
3% human Ig (Baxter International Inc., Vienna Austria)
in order to block Fc receptors and prevent non-specific
antibody binding, incubated for 15 minutes at 4°C in the
dark and stained with different combinations of fluores-
cein isothiocyanate (FITC), PE, PE-Cy5, APC and PE-Cy7
and APC-Cy7-conjugated mAb and their appropriate iso-
type controls. Intracellular staining for Foxp3 was per-
formed according to the instructions of the manufacturer
eBiosciences (San Diego, CA, USA). The samples were
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cytometry Systems, San Jose, CA, USA) using FACSDiva
software v.6.1.2 (BD Bioscience) and FlowJo software v
7.1.2 (Tree Star). Lymphocytes were gated according to
the Forward Scatter and Side Scatter. In addition gated
CD4+ cells were analyzed for the expression of CD25 and
Foxp3. Proportions of CD25+Foxp3+ and CD25−Foxp3+
cells within the gated CD4+ cells are shown. Absolute
numbers of cells were calculated from whole blood counts
obtained from routine laboratory testing.
Urine analysis
In patients with renal involvement, the extent of protein-
uria was determined by measuring total protein in a 24-
h urine collection specimen. Cells from 24-h urine sam-
ples from three patients were isolated by density gradi-
ent centrifugation. Cells were subjected to phenotypic
analysis as described above.
Statistical analysis
Values are shown throughout the manuscript as mean ±
standard error of the mean (SEM), unless stated other-
wise. Proportions of lymphocyte subpopulations were
compared using the Student t-test for normally distrib-
uted populations and if the variables were not normally
distributed we used the Kruskal-Wallis test. Relation-
ships between separate groups of data were examined
using the Pearson correlation coefficient and Spearman
rank correlation test. A P-value equal or less than 0.05
was considered significant in all statistical tests. All stat-
istical analyses were performed using GraphPad Prism
(Graph Pad Prism 4.0 by Graph Pad software Inc.) and
SPSS (SPSS 12.0 by SPSS software Inc.).
Results
Increased proportions of CD4+CD25−Foxp3+ T cells in
patients with active SLE
Freshly isolated PBMC from HC (n= 36) and SLE patients
(n = 61) were analyzed by fluorescence-activated cell sorting
(FACS) for proportions of CD4+CD25−Foxp3+ T cells. As
shown in Figure 1a proportions of CD4+CD25−Foxp3+ T
cells were significantly increased in patients with SLE (5.1 ±
0.5%) as compared to HC (1.1 ± 0.2%) (P <0.0001). To further
investigate their origin we compared CD4+Foxp3+CD25+/−T
cells from HC and SLE patients for the expression of Helios,
as a marker for thymic origin [15,16]. As shown in Figure 1b,
similar proportions of CD4+CD25+Foxp3+ T cells from HC
(87.8 ± 1%) and SLE patients (87.1 ± 1.5%) expressed Helios.
On the other hand we observed a significantly decreased per-
centage of Helios+ cells in CD4+CD25−Foxp3+ T cells in SLE
patients (63.3 ± 4%) as compared to CD4+Foxp3+CD25+
from HC (P <0.0001) or SLE patients (P <0.0001). In addition
proportions of CD4+ CD25−Foxp3+ T cells showed a signifi-
cant correlation with CD4+CD25+Foxp3+ (r= 0.7; P <0.0001)but not with CD4+CD25+Foxp3− (r = 0.17; P <0.32) in
SLE patients (Additional file 1: Figure S1). This to-
gether with our previous results [18] suggests that the
majority of CD4+CD25−Foxp3+ resemble thymic de-
rived Treg.
To determine whether the increase in CD4+CD25−Foxp3+
T cells in SLE patients is linked to a higher clinical dis-
ease activity, SLE patients were divided into patients
with active (SLEDAI score ≥6) and inactive (SLEDAI
score <6) disease (Figure 1c). Significantly higher pro-
portions of CD4+CD25−Foxp3+ T cells were observed in
active (6.9 ± 1.3%) as compared to inactive (4.1 ± 0.5%)
SLE (P = 0.01). A similar result was observed when we
compared absolute numbers of CD4+CD25−Foxp3+ T
cells in active and inactive SLE (P = 0.039).
We further correlated CD4+CD25−Foxp3+ cells with levels
of disease activity using established scores, and found signifi-
cant correlations with all tested scores: SLEDAI (r = 0.5;
P <0.001), ECLAM (r = 0.54; P <0.001) and SIS (r = 0.5;
P <0.001). In addition we observed a significant correl-
ation with anti-dsDNA antibody levels (r = 0.4; P <0.001)
and a significant inverse correlation between the levels
of complement factor C3 (r = 0.3; P = 0.01) and CH50
(r = 0.3; P = 0.01) and proportions of CD4+CD25−Foxp3+
T cells (Figure 1d). These correlations were also significant
for absolute cell numbers of CD4+CD25−Foxp3+ T cells
(data not shown). In summary CD4+CD25−Foxp3+ T
cells showed features of regulatory T cells and were
clearly linked to patients with higher disease activity.
Increased proportions of CD4+CD25−Foxp3+ T cells are
observed in SLE patients treated with cyclophosphamide
Next we determined whether increased proportions of
CD4+CD25−Foxp3+ T cells are associated with a specific im-
munosuppressive treatment regimen. As depicted in Figure 2,
significantly higher proportions of CD4+CD25−Foxp3+ T
cells were observed in SLE patients who were treated with
cyclophosphamide (11.5 ± 0.3%) as compared to patients
with other treatment regimes (4.3 ± 0.4%; P= 0.0001). No
differences in the proportions of CD4+CD25−Foxp3+ T
cells were observed in SLE patients treated with
chloroquine, methotrexate, azathioprine or mycophe-
nolate mofetil. A more detailed analysis of the SLE pa-
tients treated with cyclophosphamide, revealed that all
patients suffered from nephritis. However, when we com-
pared absolute cell numbers of CD4+CD25−Foxp3+ T cells
no significant differences were observed between the dif-
ferent treatment regimens (data not shown).
Prednisone treatment does not influence CD4+CD25−Foxp3+
T cells
Significant correlation was observed for proportions (r =
0.3; P = 0.02) and absolute cell numbers (r = 0.3; P = 0.02)


































































































































Figure 1 Increased proportions of CD4+CD25−Foxp3+ T cells in patients with active systemic lupus erythematosus (SLE). Proportions of
CD4+CD25−Foxp3+ T cells were analyzed by fluorescence-activated cell sorting (FACS) in SLE patients and healthy controls (HC). (a) A significant
increase in the percentage of CD4+CD25−Foxp3+ T cells was observed in SLE patients (n = 61) as compared to HC (n = 36) (P <0.0001). (b) The
proportion of Helios + cells was significantly reduced in CD4+CD25−Foxp3+ T cells from SLE patients as compared to CD4+CD25+Foxp3+ T cells
from HC (P <0.0001) and SLE patients (P <0.0001). (c) Percentage (P = 0.01) as well as absolute numbers (P = 0.039) of CD4+CD25−Foxp3+ T cells
were significantly increased in patients with active SLE as compared to patients with inactive SLE. (d) A significant correlation was observed for
the percentage of CD4+CD25−Foxp3+ T cells and the SLE disease activity index (SLEDAI) (r = 0.5; P <0.001), European Consensus Lupus Activity
Measurement (ECLAM) (r = 0.54; P <0.001) and SLE index score (SIS) score (r = 0.5; P <0.001), as well as the levels of dsDNA antibodies (r = 0.4;
P <0.001), C3 (r = 0.3; P = 0.01) and CH50 (r = 0.3; P = 0.01). *Significant differences.
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ally treated with higher glucocorticoid doses, we corre-
lated the daily dose of prednisone with the SLEDAI
score. Indeed we observed a significant correlation be-
tween the daily prednisone dose and the SLEDAI score(r = 0.5; P = 0.0003; Figure 3a), suggesting that increased
proportions of CD4+CD25−Foxp3+ T cells in SLE pa-
tients treated with a higher glucocorticoid dose can be ex-
plained by higher disease activity. Longitudinal analysis of a































































































Figure 2 Increased proportions of CD4+CD25−Foxp3+ T cells in patients treated with cyclophosphamide. Patients were subdivided into
groups according to their immunosuppressive treatment. MMF, mycofenolate mofetil; MTX, methotrexate; AZA, azathioprine; CYC,
cycophosphamide. Significantly higher proportions of CD4+CD25−Foxp3+ T cells were observed in systemic lupus erythematosus (SLE) patients
who were treated with cyclophosphamide as compared to patients with other treatment regimes (P = 0.0001). *Significant differences.
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one did not substantially affect proportions of CD4+
CD25−Foxp3+ T cells (Figure 3b).
Increased proportions of CD4+CD25−Foxp3+ T cells in SLE
patients with renal involvement
SLE represents a heterogenous disease with a variety of differ-
ent organ manifestations. Until now, an association of specific
organ manifestation with proportions of CD4+CD25−Foxp3+
T cells has not been investigated. We therefore divided all
SLE patients into different groups according to their organ
manifestation. In addition we further subdivided all pa-
tients into groups with active and no active organ involve-
ment at the time of Treg assessment (Figure 4).
We observed a significant increase in proportions
of CD4+CD25−Foxp3+ T cells in patients with renalinvolvement (6.7 ± 1.1%) as compared to patients with no
renal involvement (3.6 ± 0.4%; P = 0.005) and in patients
with active nephritis (7.9 ± 1.6%) as compared to SLE pa-
tients with no active nephritis (4.3 ± 0.5%; P = 0.005). In
addition, increased proportions of CD4+CD25−Foxp3+ T
cells were also observed in patients with active hematologic
involvement (7.9 ± 1.9%) as compared to patients with
no active hematologic involvement (4.5 ± 0.5%; P = 0.02).
However, when we excluded patients with active neph-
ritis from the group of patients with active hematologic
involvement, the difference lost its significance, suggest-
ing that the observed difference in patients with active
hematologic involvement was due to their concomitant
renal involvement (data not shown). No differences in pro-
portions of CD4+CD25−Foxp3+ T cells were observed for














































































































































Figure 3 (See legend on next page.)
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Figure 3 Increased proportions of CD4+CD25−Foxp3+ T cells in patients with renal manifestation. Systemic lupus erythematosus (SLE)
patients were divided into different groups according to their organ manifestations. In addition patients were subdivided into groups with (active)
and without (no active) organ involvement and at the time of the patient’s blood draw. A significant increase in proportions of CD4+CD25−Foxp3+ T cells
was observed in patients with renal manifestation (P= 0.005) and in patients with active nephritis (P= 0.005). Increased proportions of CD4+CD25−Foxp3+ T
cells were also observed in patients with active hematologic manifestations as compared to patients with no active hematologic manifestations (P= 0.02).
*Significant differences.
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T cells in patients with different organ manifestations a sig-
nificant difference was only observed in patients with renal
involvement (Additional file 2: Figure S2).
In summary, the observed increase in the percentage
and absolute cell numbers of CD4+CD25−Foxp3+ T
cells in patients with renal involvement suggests that
CD4+CD25−Foxp3+ T cells are associated with this par-
ticular organ manifestation.
CD4+CD25−Foxp3+ T cells can be detected in urine
samples of SLE patients with renal involvement and
correlate with the extent of proteinuria
Next we analyzed CD4+CD25−Foxp3+ T cells in patients
with nephritis in more detail. As depicted in Figure 5a,
CD4+CD25−Foxp3+ Tcells were also detectable in the urine
sediment of a patient with lupus nephritis. Proportions
of CD4+CD25−Foxp3+ T cells in the urine sediment were









































Figure 4 The daily glucocorticoid dose correlates with% CD4+CD25−F
activity index (SLEDAI) disease activity score. (a) The daily glucocortico
significantly correlated with the percentage of CD4+CD25−Foxp3+ T cells (r
cells (r = 0.3; P = 0.02), as well as the SLEDAI score (r = 0.5; P = 0.0003). (b) Lo
shown in a patient with high disease activity treated with prednisone.in the peripheral blood. Moreover we observed a significant
correlation between proportions of CD4+CD25−Foxp3+ T
cells and the extent of proteinuria (r = 0.4; P = 0.002) in pa-
tients with renal involvement (Figure 5b).
In order to analyze whether the correlation of
CD4+CD25−Foxp3+ T cells with the extent of proteinuria
is linked to a treatment response, we performed longitu-
dinal analysis in three SLE patients with newly diag-
nosed active kidney disease who were treated with
cyclophosphamide. As can be seen from one example
in Figure 5c we observed a decrease in proportions of
CD4+CD25−Foxp3+ T cells after the initiation of ther-
apy with cyclophosphamide. This was paralleled by a
decline in the extent of proteinuria. After seven boli of
cyclophosphamide the treatment was continued with
mycophenolat mofetil. Under this treatment, an in-
crease in proportions of CD4+CD25−Foxp3+ T cells to-
gether with an increase in the extent of proteinuria









oxp3+ T cells and the systemic lupus erythematosus disease
id dose of systemic lupus erythematosus (SLE) patients was
= 0.3; P = 0.02), and the absolute cell numbers of CD4+CD25−Foxp3+ T
ngitudinal analysis of the percentage of CD4+CD25−Foxp3+ T cells is

























































Figure 5 CD4+CD25−Foxp3+ T cells can be detected in urine samples of patients with active nephritis and correlate with the extent of
proteinuria. (a) CD4+CD25−Foxp3+ T cells were analyzed by fluorescence-activated cell sorting (FACS) in blood and urine sediment samples from
SLE patients with active nephritis. One representative dot plot is shown. (b) The percentage of CD4+CD25−Foxp3+ T cells was correlated with the
extent of proteinuria (r = 0.4; P = 0.002). (c) One representative longitudinal analysis of the percentage of CD4+CD25−Foxp3+ T cells together with
the extent of proteinuria is shown in a patient with newly diagnosed active glomerulonephritis treated with a monthly boli of cyclophosphamide.
CYC, cyclophosphamide; MMF, mycofenolate mofetil.
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In this study we analyzed the recently identified popula-
tion of CD4+CD25−Foxp3+ T cells in a cohort of SLE pa-
tients. Extended phenotypic analysis based on the
expression of the Ikaros transcription factor family mem-
ber Helios support our previous assumption [18] that the
majority of CD4+CD25−Foxp3+ T cells resemble Treg. We
further described a connection between the disease activ-
ity and peripheral blood CD4+CD25−Foxp3+ T cells. In
addition we showed for the first time that the increment
of CD4+CD25−Foxp3+ T cells is linked to a specific organ
manifestation, namely to renal involvement. A correlation
between CD4+CD25−Foxp3+ cells and the extent of pro-
teinuria further support the idea of CD4+CD25−Foxp3+
cells as a marker to recognize and monitor patients with
renal involvement.
Initial studies regarding frequencies of Treg in the per-
ipheral blood of SLE patients have generated controver-
sial results. Most groups, including our own, have
described decreased proportions of CD4+CD25high Treg
in SLE patients as compared to healthy controls and ob-
served an inverse correlation of Treg numbers with clin-
ical disease activity [7,19,29-31]. However, other studiesreported unaltered proportions or even increased pro-
portions of Treg in SLE patients and a positive correl-
ation with disease activity [17,19,32-34].
Among the overall population of CD4+CD25+ Treg we
have recently identified a population of CD4+Foxp3+ T
cells that lack the expression of CD25. Proportions of
CD4+CD25−Foxp3+ T cells were on average five-fold higher
in SLE patients as compared to HC [18]. Meanwhile this
finding has been confirmed by several other groups who
also described increased proportions of CD4+Foxp3+ T cells
that are CD25-negative or express only low levels of CD25
in SLE patients [19,21,23,34].
Helios has recently been identified as a marker to dis-
tinguish thymic-derived Treg from Treg that are induced
in the periphery [15,16]. Within this study we observed
lower proportions of Helios+ cells among CD4+CD25
−Foxp3+ T cells as compared to CD4+CD25+Foxp3+ T
cells, suggesting that CD4+CD25−Foxp3+ T cells might
reflect a combination of thymic-derived and peripherally
induced Treg cells. In addition we found significant cor-
relation between CD4+CD25−Foxp3+ T cells and CD4
+CD25+Foxp3+ bona fide Treg cells, but not with CD4
+CD25+Foxp3− T cells, representing activated T cells.
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represent regulatory T cells rather then activated T cells.
Concerning the influence of the disease activity on
proportions of CD4+CD25−Foxp3+ T cells, however, cer-
tain discrepancies exist. We therefore addressed this
question in more detail in an extended cohort of SLE
patients. Thereby we were able to describe a correlation
between proportions of CD4+CD25−Foxp3+ T cells and
disease activity in SLE patients using three different dis-
ease activity scores. Moreover, we observed significant
correlation between CD4+CD25−Foxp3+ T cells with
levels of anti-dsDNA antibodies and complement levels. In
line with our data Lin et al. reported a significant increase
of CD4+Foxp3+ T cells in patients with active SLE, deter-
mined by the SLEDAI score, as compared to patients with
inactive SLE or HC. In contrast, however, they observed no
correlation between CD4+CD25−Foxp3+ T cells and disease
activity, the complement levels and concentrations of anti-
dsDNA antibodies [34]. Suen et al. also described increased
proportions of CD25lowTreg and CD25−Treg in patients
with active and inactive SLE as compared to HC. Al-
though they focused mainly on the ratio between different
Treg subsets and effector T cells, they observed increased
proportions of CD25−Treg in patients with low comple-
ment levels. Similar observations of increased numbers of
CD4+CD25−Foxp3+ T cells in patients with active as com-
pared to inactive SLE or HC were further made by Zhang
et al. Moreover they also reported direct correlation be-
tween proportions of CD4+CD25−Foxp3+ T cells and con-
centrations of antibodies against dsDNA, whereas no
correlation was observed for the C3 levels and the SLE-
DAI score [19]. These discrepancies might be on the
one hand explained by different definitions of patients
with active and inactive SLE. On the other hand dif-
ferences might exist in the composition of the study
populations, in particular in regard to different organ
manifestation as discussed in more detail below.
To further exclude a treatment effect on the expression of
CD25 on T cells we compared proportions of CD4+CD25−
Foxp3+ T cells in SLE patients with different treatment regi-
mens. Thereby we only observed increased proportions in
patients treated with cyclophosphamide. Further analysis,
however, revealed that all cyclophosphamide-treated pa-
tients also suffered from active nephritis. In addition we ob-
served no significant differences for absolute cell numbers
of CD4+CD25−Foxp3+ T cells in SLE patients with other
treatment regimens.
Significant correlation was found between CD4+
CD25−Foxp3+ T cells and the daily cortisone dose. Pa-
tients with active SLE, however, are usually treated with a
higher cortisone dose and in fact this was confirmed by a
significant correlation between the daily cortisone dose
and the SLEDAI score. In addition we were able to fol-
low one newly diagnosed SLE patient with high diseaseactivity, and skin-, blood- and joint-manifestation, who was
treated with prednisone. This resulted in gradually reduced
disease activity without a concomitant substantial effect on
proportions of CD4+CD25−Foxp3+ T cells. Likewise, also
other studies did not describe a correlation between Treg
and the daily cortisone dose in SLE patients [17,23] except
for Zhang et al. who observed decreased proportions of
CD4+CD25−Foxp3+ T cells after treatment of active SLE
with cortisone [19]. An explanation for this discrepancy
might be the different treatment regimen, as all patients in
the study by Zhang et al. also received cyclophospha-
mide at the same time. On the other hand, differences
in the organ manifestations might contribute to this
discrepancy.
As a systemic autoimmune disease SLE can affect al-
most any organ system and most patients display multi-
organ involvement with unpredictable exacerbations
and remissions with protean clinical manifestations.
The most common organs that are involved are the
skin, the musculoskeletal system and the kidneys. Organ
systems may be involved singly or in any combination.
Until now the association of a certain organ manifestation
with the presence of different T cell subsets has not been
investigated so far. As we also observed an increase of
CD4+CD25−Foxp3+ T cells in cyclophosphamide-treated
patients who suffered from active nephritis we compared
CD4+CD25−Foxp3+ T cells in patients with active and
no active organ involvement. Interestingly, patients with
renal involvement, especially patients with active nephritis,
displayed increased proportions of CD4+CD25−Foxp3+ T
cells, suggesting that the observed increase was mainly as-
sociated with renal organ involvement. We also observed
elevated numbers in patients with active blood involve-
ment. This observation, however, was mainly due to an
overlap in the organ manifestation since most of the
patients with hematologic manifestations also suffered
from renal involvement. When we compared absolute cell
numbers of CD4+CD25−Foxp3+ T cells, we only observed a
significant difference in patients with renal involvement, but
not in patients with hematologic manifestation. Further-
more CD4+CD25−Foxp3+ T cells were also detected in the
urine sediment of patients with active nephritis. In addition
we also observed significant correlation between the CD4+
CD25−Foxp3+ T cells and the extent of proteinuria, reflect-
ing the disease activity in patients with active nephritis. Lon-
gitudinal analysis of patients with active nephritis
revealed a decline in CD4+CD25−Foxp3+ T cells under
cyclophosphamide treatment in parallel to a drop in the
extent of proteinuria and the disease activity. The paral-
lel decrease and increase of CD4+CD25−Foxp3+ T cells
with the disease activity in SLE patients with renal
manifestation might reflect the potential of CD4+CD25−
Foxp3+ T cells as a biomarker to diagnose and monitor
SLE patients with active kidney involvement.
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http://arthritis-research.com/content/16/2/R104One of the key questions remains whether CD4+
CD25−Foxp3+ T cells actually represent a beneficial counter-
mechanism against autoimmunity, or on the contrary,
if these cells are part of the damaging auto-immunological
machinery of SLE. In fact Treg display a certain plasticity, in
particular under inflammatory conditions, and might even
transdifferentiate into pathogenic effector T cells. However,
until an activation-independent surface marker molecule is
found for Treg, this question cannot be answered to date.
On the other hand, irrespective of their functional capacity,
CD4+CD25−Foxp3+ T cells might be of interest in SLE pa-
tients as a marker of disease activity, organ manifestation or
treatment response.
In conclusion we were able to demonstrate that this newly
described cell population of CD4+CD25−Foxp3+ T cells is
clearly influenced by the disease activity and that an increase
of this cell population is mainly observed in patients with
renal involvement. The correlation with the extent of pro-
teinuria suggests that the assessment of CD4+CD25−Foxp3+
cells can be used as a tool to recognize and monitor SLE pa-
tients with renal involvement.
Conclusion
CD4+CD25−Foxp3+ T cells resemble a marker for lupus
nephritis. CD4+CD25−Foxp3+ T cells represent a subpopu-
lation of Treg and are increased in SLE patients with high
disease activity. Here we show that CD4+CD25−Foxp3+ T
cells are significantly increased in patients with renal in-
volvement. Longitudinal data of patients with lupus neph-
ritis further support the idea that CD4+CD25−Foxp3+ T
cells might serve to recognize and monitor SLE patients
with renal involvement.Additional files
Additional file 1: Figure S1. CD4+CD25−Foxp3+ T cells correlate with
regulatory T cells but not with activated T cells. CD4+CD25−Foxp3+ T cells
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CD4+CD25−Foxp3+ T cells in patients with renal manifestation. Systemic
lupus erythematosus (SLE) patients were divided into different groups
according to their organ manifestations. In addition patients were
subdivided into groups with active and no active organ involvement. A
significant increase in absolute cell numbers of CD4+CD25−Foxp3+ T cells
was observed in patients with renal involvement (P = 0.01) and in
patients with active nephritis (P = 0.04). *Significant differences.Abbreviations
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